{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:07:06Z","timestamp":1784358426997,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.3816\/ccc.2004.n.018","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:05Z","timestamp":1221080765000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["Dihydropyrimidine Dehydrogenase Deficiency, a Pharmacogenetic Syndrome Associated with Potentially Life-Threatening Toxicity Following 5-Fluorouracil Administration"],"prefix":"10.3816","volume":"4","author":[{"given":"Hany","family":"Ezzeldin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2004.n.018_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"10.3816\/CCC.2004.n.018_bib2","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2004.n.018_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv Enzyme Regul"},{"key":"10.3816\/CCC.2004.n.018_bib4","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib5","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib6","first-page":"149","article-title":"5-Fluoropyrimidines","volume":"Vol. 2","author":"Grem","year":"1996"},{"key":"10.3816\/CCC.2004.n.018_bib7","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib8","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2004.n.018_bib9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1172\/JCI118830","article-title":"Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity","volume":"98","author":"Wei","year":"1996","journal-title":"J Clin Invest"},{"key":"10.3816\/CCC.2004.n.018_bib10","first-page":"325","article-title":"Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy","volume":"4","author":"Lu","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J Clin Invest"},{"key":"10.3816\/CCC.2004.n.018_bib12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/35015728","article-title":"Pharmacogenetics and the practice of medicine","volume":"405","author":"Roses","year":"2000","journal-title":"Nature"},{"key":"10.3816\/CCC.2004.n.018_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response","volume":"348","author":"Weinshilboum","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2004.n.018_bib14","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib15","first-page":"83","article-title":"Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy","volume":"24","author":"Morrison","year":"1997","journal-title":"Oncol Nurs Forum"},{"key":"10.3816\/CCC.2004.n.018_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.3816\/CCC.2004.n.018_bib17","series-title":"Scrip's Cancer Chemotherapy Report. Scrip World Pharmaceutical News","year":"2002"},{"key":"10.3816\/CCC.2004.n.018_bib18","series-title":"Concepts, mechanisms, and new targets for chemotherapy","first-page":"71","article-title":"Fluoropyrimidine catabolism","author":"Diasio","year":"1995"},{"key":"10.3816\/CCC.2004.n.018_bib19","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1016\/S0021-9258(18)41899-6","article-title":"Purification and characterization of dihydropyrimidine dehydrogenase from human liver","volume":"267","author":"Lu","year":"1992","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2004.n.018_bib20","series-title":"Mechanisms of toxicity of anticancer drugs, a study in human toxicity","article-title":"Toxicity of antimetabolites","author":"Sweeny","year":"1991"},{"key":"10.3816\/CCC.2004.n.018_bib21","article-title":"Metabolism of pyrimidine analogues and their nucleosides","volume":"Vol. 1","author":"Daher","year":"1994"},{"key":"10.3816\/CCC.2004.n.018_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","article-title":"Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome","volume":"68","author":"Harris","year":"1991","journal-title":"Cancer"},{"key":"10.3816\/CCC.2004.n.018_bib23","first-page":"477","article-title":"Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency","volume":"2","author":"Takimoto","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib24","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib25","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls","volume":"7","author":"Raida","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"Van Kuilenburg","year":"1999","journal-title":"Hum Genet"},{"key":"10.3816\/CCC.2004.n.018_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s004390050637","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W","volume":"101","author":"Vreken","year":"1997","journal-title":"Hum Genet"},{"key":"10.3816\/CCC.2004.n.018_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD alleles do not explain DPD deficiency in cancer patients","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2004.n.018_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00008571-199704000-00012","article-title":"Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin","volume":"7","author":"Fernandez-Salguero","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2004.n.018_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1005357307122","article-title":"Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene","volume":"20","author":"Vreken","year":"1997","journal-title":"J Inherit Metab Dis"},{"key":"10.3816\/CCC.2004.n.018_bib31","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"van Kuilenburg","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00751.x","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects","volume":"46","author":"Ridge","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CCC.2004.n.018_bib33","first-page":"2999","article-title":"Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity","volume":"4","author":"Kouwaki","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib34","first-page":"3021","article-title":"Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity","volume":"9","author":"Ezzeldin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1349-7006.2001.tb01100.x","article-title":"Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil","volume":"92","author":"Yamaguchi","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib36","first-page":"5433","article-title":"Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy","volume":"53","author":"Lu","year":"1993","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib37","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2004.n.018_bib38","first-page":"740","article-title":"Dihydropyrimidine dehydrogenase activity in cancer patients","volume":"29A","author":"Fleming","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.3816\/CCC.2004.n.018_bib39","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2004.n.018_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.3816\/CCC.2004.n.018_bib42","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0006-2952(93)90505-Q","article-title":"Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties","volume":"46","author":"Lu","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CCC.2004.n.018_bib43","doi-asserted-by":"crossref","first-page":"23192","DOI":"10.1016\/S0021-9258(17)31638-1","article-title":"cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria","volume":"269","author":"Yokota","year":"1994","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2004.n.018_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/10425179609008450","article-title":"cDNA cloning of bovine liver dihydropyrimidine dehydrogenase","volume":"6","author":"Albin","year":"1996","journal-title":"DNA Sequence"},{"key":"10.3816\/CCC.2004.n.018_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00008571-200203000-00007","article-title":"A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms","volume":"12","author":"Mattison","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2004.n.018_bib46","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/emboj\/20.4.650","article-title":"Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil","volume":"20","author":"Dobritzsch","year":"2001","journal-title":"EMBO J"},{"key":"10.3816\/CCC.2004.n.018_bib47","doi-asserted-by":"crossref","first-page":"13155","DOI":"10.1074\/jbc.M111877200","article-title":"Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-ioduracil. Implications for mechanism of inhibition and electron transfer","volume":"277","author":"Dobritzsch","year":"2002","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2004.n.018_bib48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1006\/geno.1994.1680","article-title":"Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization","volume":"24","author":"Takai","year":"1994","journal-title":"Genomics"},{"key":"10.3816\/CCC.2004.n.018_bib49","first-page":"1660","article-title":"Structural organization of the human dihydropyrimidine dehydrogenase gene","volume":"57","author":"Johnson","year":"1997","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/geno.1998.5379","article-title":"Characterization of the human dihydropyrimidine dehydrogenase gene","volume":"51","author":"Wei","year":"1998","journal-title":"Genomics"},{"key":"10.3816\/CCC.2004.n.018_bib51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0167-4781(00)00213-X","article-title":"Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter","volume":"1494","author":"Shestopal","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.3816\/CCC.2004.n.018_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00008571-199812000-00001","article-title":"Nomenclature for human DPYD alleles","volume":"8","author":"McLeod","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2004.n.018_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256180","article-title":"The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil","volume":"21","author":"Gardiner","year":"2002","journal-title":"Adverse Drug React Toxicol Rev"},{"key":"10.3816\/CCC.2004.n.018_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/bj3640157","article-title":"Novel diseasecausing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure","volume":"364","author":"van Kuilenburg","year":"2002","journal-title":"Biochem J"},{"key":"10.3816\/CCC.2004.n.018_bib55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/978-1-4615-5381-6_68","article-title":"Dihydropyrimidine dehydrogenase deficiency. Identification of two novel mutations and expression of missense mutations in E. coli","volume":"431","author":"Vreken","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.3816\/CCC.2004.n.018_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.1995.14.1","article-title":"Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea","volume":"14","author":"Meinsma","year":"1995","journal-title":"DNA Cell Biol"},{"key":"10.3816\/CCC.2004.n.018_bib57","first-page":"322A","article-title":"High-throughput mutation screening of the DPYD gene by denaturing HPLC","volume":"43","author":"Gross","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib58","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.1998.79","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer","volume":"77","author":"Ridge","year":"1998","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2004.n.018_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1023\/A:1005384609289","article-title":"Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G\u2013>A point mutation","volume":"21","author":"van Kuilenburg","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"10.3816\/CCC.2004.n.018_bib60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1023\/A:1005328424310","article-title":"Clinical variability in three Danish patients with dihydropyrimidine dehydrogenase deficiency all homozygous for the same mutation","volume":"21","author":"Christensen","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"10.3816\/CCC.2004.n.018_bib61","first-page":"211A","article-title":"Initial characterization of the molecular defect in human dihydropyrimidine dehydrogenase deficiency","volume":"36","author":"Albin","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1005380525218","article-title":"Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli","volume":"21","author":"Vreken","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"10.3816\/CCC.2004.n.018_bib63","series-title":"Handbook of Anticancer Drug Development","article-title":"Pharmacogenetics and Cancer Chemotherapy","author":"Ezzeldin","year":"2003"},{"key":"10.3816\/CCC.2004.n.018_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-1-4615-2584-4_2","article-title":"Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD","volume":"370","author":"Diasio","year":"1994","journal-title":"Adv Exp Med Biol"},{"key":"10.3816\/CCC.2004.n.018_bib65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0009-8981(02)00132-8","article-title":"Development and characterization of a monoclonal antibody with cross-reactivity towards uracil and thymine, and its potential use in screening patients treated with 5-fluorouracil for possible risks","volume":"322","author":"Honda","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.3816\/CCC.2004.n.018_bib66","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1067\/mcp.2002.128867","article-title":"Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer","volume":"72","author":"Di Paolo","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.3816\/CCC.2004.n.018_bib67","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","article-title":"Rapid identification of dihydropyrimidine dehydrogenase (DPD) deficiency by a novel 2-13C-uracil breath test (UBT)","volume":"10","author":"Mattison","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2004.n.018_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","article-title":"A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency","volume":"306","author":"Ezzeldin","year":"2002","journal-title":"Anal Biochem"},{"key":"10.3816\/CCC.2004.n.018_bib69","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: translating functional genomics into rational therapeutics","volume":"286","author":"Evans","year":"1999","journal-title":"Science"},{"key":"10.3816\/CCC.2004.n.018_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0968-0004(01)02008-4","article-title":"Protein Explorer: easy yet powerful macromolecular visualization","volume":"27","author":"Martz","year":"2002","journal-title":"Trends Biochem Sci"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811701153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811701153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:58:19Z","timestamp":1761519499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811701153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S1533002811701153"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2004.n.018","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydropyrimidine Dehydrogenase Deficiency, a Pharmacogenetic Syndrome Associated with Potentially Life-Threatening Toxicity Following 5-Fluorouracil Administration","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2004.n.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}